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The term neurodevelopmental disorder (NDD) is an umbrella term used to group
together a heterogeneous class of disorders characterized by disruption in cognition,
emotion, and behavior, early in the developmental timescale. These disorders
are heterogeneous, yet they share common behavioral symptomatology as well
as overlapping genetic contributors, including proteins involved in the formation,
specialization, and function of synaptic connections. Advances may arise from bridging
the current knowledge on synapse related factors indicated from both human studies
in NDD populations, and in animal models. Mounting evidence has shown a link to
inhibitory synapse formation, specialization, and function among Autism, Angelman,
Rett and Dravet syndromes. Inhibitory signaling is diverse, with numerous subtypes
of inhibitory interneurons, phasic and tonic modes of inhibition, and the molecular
and subcellular diversity of GABAA receptors. We discuss common ribs of inhibitory
synapse dysfunction in the umbrella of NDD, highlighting alterations in the
developmental switch to inhibitory GABA, dysregulation of neuronal activity patterns
by parvalbumin-positive interneurons, and impaired tonic inhibition. Increasing our
basic understanding of inhibitory synapses, and their role in NDDs is likely to
produce significant therapeutic advances in behavioral symptom alleviation for
interrelated NDDs.
Keywords: neurodevelopment, GABA A receptor, autism spectrum disorders, Rett Syndrome (RTT), Angelman
Syndrome, Dravet Syndrome, seizures, phasic and tonic inhibition
Highlights:
•Human studies and animal models need to be bridged in neurodevelopmental disorders
• Inhibitory signaling emerges as a common contributor to neurodevelopmental disorders
• Inhibitory signaling is diverse in mode, source, and target
• Systematic evaluation of inhibitory diversity is lacking in neurodevelopment
• Understanding of inhibitory signaling diversity will advance therapeutic strategies
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INTRODUCTION
Neurodevelopmental disorders (NDDs) are a broad class of
disorders involving disruption in one or more domains including
cognitive, emotional, motor, and/or behavioral function. NDDs
affect up to 36.8% of children in low- and middle-income earning
countries as evaluated in 2015 (Boivin et al., 2015; McCoy
et al., 2016). Although NDDs have been the subject of extensive
research, the common underlying mechanisms for behavioral and
neurobiological symptomatology have yet to be systematically
evaluated and compared among broad NDD subtypes. A basis for
commonality among this complex and seemingly heterogeneous
class of disorders lies in shared symptomatology (Table 1)
and common genetic factors (Table 2). Further, genetic studies
are beginning to indicate converging biological and phenotypic
traits in complex disorders such as NDDs (Parikshak et al.,
2016).
Autism spectrum disorder (ASD) is a prototypical NDD,
and acts as a reference point for this class of disorders,
with others often being described as possessing “autistic-like
features.” Features of ASD include any range of impairments
in social interaction, language development, and cognition,
along with stereotyped behavior, and restricted interests (Rapin
and Katzman, 1998). In addition to these core features, ASD
is also frequently associated with epilepsy, impaired sensory
processing, hyperactivity, and disrupted brain activity patterns
as characterized by electroencephalogram (EEG) recordings
(Rubenstein and Merzenich, 2003). These associated symptoms,
in particular, hint that impaired inhibitory signaling is a
contributor to ASD.
Other NDDs with similar symptoms to ASD, including Rett
Syndrome (RS) and Angelman Syndrome (AS), have a clear
genetic cause (Table 2). Specifically, RS is linked to the MECP2
gene (Banerjee et al., 2012), and AS linked to UBE3A and/or
GABAAR subunit dysfunction through a loss of activity within
the 15q11-13 locus (Malzac et al., 1998). The monogenetic
nature of these disorders raises them as attractive targets to
begin investigating NDDs. This is in contrast to ASD that is
linked to an extremely heterogeneous and inconsistent genetic
profile (Hu and Steinberg, 2009; Hu et al., 2009). Strikingly, RS
and AS often share features of ASD, including the associated
symptoms indicative of impaired inhibitory signaling. RS and AS
also have a high incidence of epilepsy, with the vast majority
of patients being affected by seizures (Fiumara et al., 2010;
Vignoli et al., 2017). Comparing and contrasting the current
knowledge on these disorders stands to provide information
about the common neuropathological underpinnings of NDDs.
TABLE 1 | Brief overview of symptom commonalities in NDDs.
Neurodevelopmental
disorder
Autism-like
characteristics
Intellectual
disability
Epilepsy
Autism Characteristic Common Prevalent
Angelman Prevalent Common Prevalent
Rett Prevalent Common Prevalent
Dravet Rare Common Characteristic
In particular, examination of their association with epilepsy and
other indications of impaired inhibitory control of principal cell
firing, alongside an analysis of inhibitory synapse dysfunction
could advance our understanding.
In typical development of the central nervous system,
excitatory and inhibitory signals work in concert achieving
regulated and orchestrated signaling patterns or oscillations.
This tenet is the basis for a theory originally proposed by
Rubenstein and Merzenich (2003), which suggests that NDDs
are the result of an atypical “balance” between excitation and
inhibition. An “imbalance” is proposed to increase the signal-to-
noise ratio and decrease the efficiency of processing in aﬄicted
individuals, leaving the cortex susceptible to seizures and other
dysfunctional symptoms linked to hyperexcitability (Rubenstein
and Merzenich, 2003). Mounting evidence is demonstrating that
a number of genetic mutations can disrupt this balance, and
in the case of NDDs, can tip the balance toward excitation at
the expense of inhibition, contributing to multiple symptoms
including a lower seizure threshold and a high incidence
of epilepsy. Although the concept of an excitatory-inhibitory
balance has been useful in understanding pathological and non-
pathological brain states, it is likely an oversimplification and
may not be sufficient to explain the immense heterogeneity and
complex etiology of NDDs.
To advance from the excitatory-inhibitory balance hypothesis
we need to understand synapses more fundamentally in the
brain, particularly during development. We need both more
detailed understanding of the developmental regulation of
specific synapse types and implications for network activity,
as well as more global understanding of the functional
intersection between molecular and ionic states, synapse
types, and network signaling during development. The current
state of knowledge on inhibitory synapse development and
regulation is limited compared to that of excitatory glutamatergic
synapses. Furthering research in the field of inhibitory synapse
development is essential to gaining insight into how this system
impacts typical and atypical neurodevelopment. This review will
examine the commonalities between seemingly heterogeneous
NDDs, highlighting common genetic links and evidence of
inhibitory synaptic dysfunction, in pursuit of a common rib in
the umbrella of NDD.
INHIBITORY SIGNALING
Neuronal network signaling relies not only on excitation, but also
heavily on inhibition to spatially and temporally pattern principal
cell activity. Inhibition in the brain is governed by interneurons
that synthesize and release the neurotransmitter γ-aminobutyric
acid (GABA). A large body of work has documented and
characterized 16 subtypes of interneurons in the hippocampus
and/or cortex that possess unique morphologies, differential
protein expression patterns, and specialized connectivity,
physiological function, and functional impact within neuronal
networks (Figure 1; Klausberger and Somogyi, 2008; Petilla
Interneuron Nomenclature Group et al., 2008). A number of
these interneuron types are relevant to the investigation of
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inhibitory signaling in NDD, due to their enrichment in cortical
circuitry, and implication in patterning network activity. The
majority of hippocampal and cortical interneurons express
either the calcium binding protein Parvalbumin (PV), or the
neuropeptide cholecystokinin (CCK) (Klausberger and Somogyi,
2008; Petilla Interneuron Nomenclature Group et al., 2008).
PV-positive axo-axonic chandelier cells innervate the axon initial
segment (AIS) of principal cells at or near the site of action
potential generation, and can coordinate the activity of the up to
1,200 cells that they innervate (Li et al., 1992; Klausberger and
Somogyi, 2008; Petilla Interneuron Nomenclature Group et al.,
2008). PV-positive and CCK-positive basket cells innervate the
soma and proximal dendrites of principal cells, and again play
a role in coordinating activity patterns due to proximity to the
AIS (Freund and Katona, 2007; Klausberger and Somogyi, 2008;
Petilla Interneuron Nomenclature Group et al., 2008). In the
cortex, Martinotti cells express the neuropeptide somatostatin
(SOM) and innervate the dendrites of principal cells, providing
local effects on incoming excitatory input (Rudy et al., 2011).
In addition, hippocampal and cortical networks also include
interneurons that innervate interneurons, thereby acting in a
disinhibitory manner (Figure 1). One example in the cortex is a
type of bipolar cell that is positive for the neuropeptide vasoactive
intestinal polypeptide (VIP), which have been shown to target
the majority of PV-positive interneurons (Dávid et al., 2007).
Once released by interneurons, GABA acts on ionotropic
GABA type A receptors (GABAARs; as well as metabotropic
GABA type B receptors). GABAARs are heteropentamers gating
a chloride channel, composed of combinations of subunits
from seven families: α(1-6), β(1-3), γ(1-3), δ, ε, θ, pi, and
ρ(1-3) (Rudolph and Möhler, 2006). The genes and protein
products for the most abundant CNS subunits are briefly
described in Table 2 and depicted in Figure 2. Subtypes of
GABAARs composed of different subunit combinations have
specific localization patterns and diverse functional impacts.
In addition, GABAARs can be found at both synaptic and
extrasynaptic sites mediating functionally distinct modes of
inhibition (Figure 2). The most abundant subtypes of GABAARs
are synaptic, sensitive to benzodiazepines, and composed of α1-
3, β1-3, and γ2 subunits (Lüscher and Keller, 2004; Rudolph
and Möhler, 2006; Jacob et al., 2008). In contrast, extrasynaptic,
benzodiazepine insensitive receptors typically contain α4-6, β2/3,
and δ subunits (Herd et al., 2013).
In addition to modulation by benzodiazepines, synaptic
GABAARs are also the site of action for non-benzodiazepine
Z-drugs (Dixon et al., 2015), and barbiturates, while extrasynaptic
GABAARs are thought to be the site of action of intravenous
and inhaled anesthetics (Chiara et al., 2016), anesthetic steroids,
neurosteroids and other exogenous modulators such as ethanol
(Brickley and Mody, 2012; Sigel and Steinmann, 2012; Olsen,
2015). In addition to clinically relevant ligands, there are also a
number of preclinical or experimental ligands such as muscimol
(synaptic), and gaboxadol (extrasynaptic), and the channel
blocker picrotoxin (Sigel and Steinmann, 2012; Olsen, 2015).
The diversity of localization and function, paired with the clear
clinical and behavioral impact of pharmacological manipulation,
make GABAARs an important target of study.
FIGURE 1 | Interneurons contact multiple domains of their postsynaptic
targets producing different forms of phasic inhibition. Somatostatin (SOM)
positive Martinotti cells contact the dendritic domain to provide local inhibitory
influences on excitatory inputs. Basket cells positive for CCK contact the
soma where GABAARs containing the α2/3 subunits are enriched, while
basket cells positive for parvalbumin (PV) contact the cell body at sites
enriched with α1 containing GABAARs. PV positive chandelier cells project to
the axon initial segment where GABAARs containing the α2 subunit are
enriched. Somatic and axonal inhibition plays a role in coordinating neural
activity patterns due to the proximity of the incoming graded potentials to the
site of action potential generation. Disinhibitory interneurons innervate other
interneurons providing net excitation, as seen with vasoactive intestinal
polypeptide (VIP) positive bipolar cells.
Synaptic GABAA Receptors – Phasic
Inhibition
GABAARs located at synaptic contacts are activated in a transient
or ‘phasic’ manner by a high concentration of GABA released
from presynaptic vesicles (Figure 2, right). GABA released from
the presynaptic neuron bind to GABAARs gating a channel
permeable to chloride and bicarbonate ions at the postsynaptic
membrane. Generally, this leads to a net inward flow of anions,
and a hyperpolarizing postsynaptic response known as the
inhibitory postsynaptic potential (IPSP). Defining features of this
phasic mode of receptor activation are the rapid synchronous
opening of a relatively small number of channels that are
clustered at the synaptic junction and the short duration of the
GABA transient to which the postsynaptic receptors are exposed.
Phasic receptors enriched at synapses are most commonly
characterized by two α(1-3), two β, and one γ subunit.
The clustering and accumulation of GABAARs at synaptic
sites relies upon the interaction of multiple receptor-associated,
adhesion, and scaffolding proteins diagramed in Figure 2,
including gephyrin (Tretter et al., 2008, 2011; Mukherjee
et al., 2011), collybistin (Saiepour et al., 2010), neuroligin 2
(Chih et al., 2005; Poulopoulos et al., 2009), neurexin (Zhang
et al., 2010), and the dystroglycan, dystrophin–glycoprotein
complex (Panzanelli et al., 2011; Früh et al., 2016). Despite
a common pool of interacting proteins, heterogeneity exists
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FIGURE 2 | Molecular characterization of phasic and tonic modes of inhibition. Fast inhibitory synaptic transmission, also known as phasic inhibition, is governed by
GABAAR’s with relatively low sensitivity to GABA densely clustered at sites opposing interneuron terminal boutons. Several general factors have been identified that
play a role in establishing the contact between pre and post (neurexin-neuroligin2/3; neurexin-dystroglycan), and/or retaining receptors at these sites (gephyrin,
collybistin). Phasic GABAARs are most commonly composed of 2-α1-3, 2-β, and a γ subunit and are sensitive to benzodiazepines. Tonic inhibition is governed by
GABAAR’s that reside outside of synaptic sites, are highly sensitive to GABA, and are most commonly composed of 2-α4-6, 2-β, and a δ subunit. Much less is
known about the mechanisms that localize extrasynaptic GABAARs, but radixin is implicated.
in the complex mechanisms governing clustering of receptors
containing different subunits. Composition is likely dependent
upon the combination of interacting proteins involved, and their
relative interaction affinities.
Inhibitory synapses that generate phasic inhibitory signals
can be found on multiple compartments of the cell including
the dendrites, axon, and cell body (Figure 1). For example,
receptors containing α1 subunits are enriched at inhibitory
synapses on the dendrites, those containing α2 subunits are
preferentially enriched at inhibitory synapses on the AIS, and
both α1 and α2 subunits can be found clustered at somatic
inhibitory synapses (Figure 1; Nusser et al., 1996; Freund and
Katona, 2007; Gao and Heldt, 2016). AIS synapses are unique
to principal neurons in the hippocampus and cortex, and are
thought to control principal cell activity patterns by influencing
the site of action potential generation (Kuba et al., 2010;
Wefelmeyer et al., 2015). As mentioned above, AIS synapses
originate from chandelier cells, which are highly specialized, fast-
spiking, PV-positive interneurons (Li et al., 1992; Klausberger
and Somogyi, 2008; Petilla Interneuron Nomenclature Group
et al., 2008). The cortex is also enriched with PV-positive, fast-
spiking basket cells, and CCK positive basket cells. CCK positive
basket cell terminals contact the soma of pyramidal cells where
clusters of GABAARs containing the α2/3 subunits are enriched
(Nyíri et al., 2001). The formation and maintenance of CCK
terminals on the soma has recently been linked to dystroglycan,
a protein responsible for many inherited forms of muscular
dystrophy (Figure 1; Früh et al., 2016). Outside of the role for
dystroglycan in CCK-basket cell contacts on the soma, detailed
information about the mechanisms of other specialized subtypes
of inhibitory synapses, such as those localized to the AIS is
lacking.
In addition to localization and related impacts on function,
subunit contents have also been shown to influence the
physiological properties of GABAARs including the decay time
of GABA-activated currents within single cells. Presence of a β2
subunit results in a decreased period of time in which the receptor
chloride channel is open—leading to faster desensitization.
In contrast, the γ2 subunit results in channels with larger
conductance (Verdoorn et al., 1990). In addition, α1 subunit
containing receptors show faster decay times compared to α2
containing receptors (Lavoie et al., 1997; Eyre et al., 2012).
Extrasynaptic GABAA Receptors – Tonic
Inhibition
GABAAR activation can also take place in a less spatially and
temporally restricted manner to generate a ‘tonic’ conductance
(Nusser et al., 1998; Farrant and Nusser, 2005; Hines et al.,
2012; Lee and Maguire, 2014). Low GABA concentrations in
the extracellular space escaping from the synaptic cleft can
activate GABAARs distant from sites of neurotransmitter release
(Figure 2, left; Farrant and Nusser, 2005; Hines et al., 2012).
The tonic mode of receptor activation has one straightforward
outcome: a persistent increase in the cell’s input conductance.
This increase in conductance affects the magnitude and duration
of the voltage response to an injected current, and increases
the decrement of voltage with distance (Farrant and Nusser,
2005; Bright and Smart, 2013). Tonic GABAARs exhibit a high
sensitivity to GABA and show little desensitization, allowing
them to detect and respond to ambient levels of GABA
at extrasynaptic sites (Nusser and Mody, 2002; Farrant and
Nusser, 2005; Hines et al., 2012). Tonic receptors are most
commonly characterized by two α(4-6), two β and one δ subunit
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(Figure 2, left). GABAARs containing δ subunits tend to be purely
extrasynaptic (Farrant and Nusser, 2005; Lee and Maguire, 2014).
The α4 and α6 subunits are diazepam-insensitive receptors,
as their inclusion results in decreased sensitivity to complete
desensitization to benzodiazepine binding on the receptor
(Whiting et al., 1995). While the complex mechanisms governing
localization of GABAARs at synaptic sites have been somewhat
clarified, very little is known about the mechanisms that are
involved in regulation of extrasynaptic GABAARs. One of the
few proteins implicated in regulation of extrasynaptic GABAARs
is radixin, which has been shown to influence clustering of
α5 containing receptors (Figure 2, left; Loebrich et al., 2006).
Further research is needed to understand how these receptors are
localized and regulated, and also to understand further how their
action may be harnessed to control excitation.
Chloride Ion Reversal and GABA
Signaling
Another factor that can modulate the efficacy of GABAergic
inhibition is the reversal potential for GABAA (EGABA)
receptor-mediated current and voltage responses. EGABA is
controlled by the equilibrium potential for chloride (ECl)
which in turn is regulated by the expression and function
of cation-chloride cotransporters (CCCs; Rivera et al., 2005;
Ben-Ari et al., 2007; Ben-Ari, 2014; Kaila et al., 2014). Two
key members of the CCC family for controlling neuronal
ECl are the potassium chloride cotransporter (KCC2) and
the sodium potassium chloride cotransporter (NKCC1) which
provide outwardly and inwardly directed chloride fluxes in
neuronal cells, respectively (Ben-Ari et al., 2007; Hartmann
and Nothwang, 2014; Doyon et al., 2016). In mature neurons,
chloride is extruded by high levels of expression and function
of KCC2, using the potassium gradient in order to maintain a
low intracellular chloride concentration (Ben-Ari et al., 2007;
Doyon et al., 2016). A low intracellular concentration of chloride
is important to maintaining the driving force of chloride, such
that when GABA binds, chloride will enter the cell through
the pore of the GABAAR and hyperpolarize the cell (Ben-
Ari, 2014; Kaila et al., 2014). Early in development, KCC2 is
low in expression and activity in neurons leading to a high
intracellular chloride concentration (Ben-Ari et al., 2007; Ben-
Ari, 2014). High levels of chloride inside the neuron cause
depolarization in response to GABAAR activation, and under
specific conditions, excitatory GABAergic transmission (Rivera
et al., 2005; Ben-Ari et al., 2007; Kaila et al., 2014). Excitatory
GABA is proposed to play a trophic role in early development,
with important effects on the cell cycle, cell migration, and
primitive oscillatory patterns thought to influence network
wiring (Represa and Ben-Ari, 2005). During development there
is a caudal to rostral gradient in the increase of KCC2
expression, with the cortex showing continued increases in
KCC2 expression well after birth (Kaila et al., 2014). Beyond
the developmental state of high intracellular chloride and
depolarizing GABA, it is now established that pathological
states including epilepsy and trauma are also characterized
by reduced KCC2 expression and high intracellular chloride
(Kaila et al., 2014). Further understanding is required about
the conditions for inducing change in the expression of KCC2,
and also for the implications, that this has on circuit level
function.
Understanding the distinctive functional contributions of
GABAergic synapses on specific subcellular compartments,
phasic and tonic forms of GABAergic signaling, as well as the
impact of alterations in ECl will lead to greater ability to fine tune
inhibitory signaling. An understanding that is currently lacking is
of the neurodevelopmental processes that establish and maintain
the structurally and functionally distinctive types of GABAergic
synapses, as well as the roles for tonic inhibition throughout
development. Further, we are continuing to understand the roles
of excitatory GABA early in development. We need to evaluate
perturbations in each of these specializations of GABAergic
signaling in NDDs with a subunit specific, cell-domain specific
level of detail, deciphering precisely which subtypes of GABAARs
are affected, and what role the transition from excitatory to
inhibitory GABA may play. In the following sections, we will
describe the features of specific NDDs and highlight existing
studies that have assessed GABAergic signaling in either NDD
populations or disease models.
AUTISM SPECTRUM DISORDERS
Autism spectrum disorder affects boys more commonly than
girls, with a ratio between 3:1 and 4:1, with a prevalence of 1 in
54 boys (Coury et al., 2014; Loomes et al., 2017). The disorder is
characterized by core symptomatology that includes compulsive
or repetitive behaviors and social communication deficits
(American Psychiatric Association, Diagnostic and Statistical
Manual 5th edn). These core symptoms are often accompanied by
intellectual disability, sensory sensitivity, and seizures. Seizures
(and/or epilepsy) occur in ∼30–60% of individuals with ASD
(Rubenstein and Merzenich, 2003; Jacob, 2016). Historically, the
relationship between ASD and abnormal EEG recordings was
the first reason it was considered a brain disorder (Banerjee
et al., 2014). This suggests that altered oscillatory activity is a
prominent feature of ASD. The heritability of ASD has been
studied in family and twin studies and shows a heritability
rate of 70% (Tick et al., 2016). Accumulating genomic/genetic
investigations indicate hundreds of genetic variants in the
occurrence of ASD, including a range from common to rare
variants (Krumm et al., 2014). Several of these identified
genetic mutations producing autistic-like behaviors have been
investigated in mouse models. Despite extensive research in
human populations and mouse models, no unifying cause has
been determined.
Multiple genetic contributors to ASD are synaptic proteins,
and in particular can be classified as trans-synaptic adhesion
molecules, or synaptic scaffolding proteins, or synaptic signaling
proteins (Table 2). Specific genes implicated within these
categories are discussed in detail below: adhesion molecules
from the neurexin, neuroligin, and contactin families; synaptic
scaffolding proteins from the shank family; and GABAAR subunit
genes within the 15q11–13 locus.
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Adhesion Molecules: Neuroligin,
Neurexin and Contactin Families of
Proteins
The neurexin (NRXN/Nrxn), neuroligin (NLGN/Nlgn), and
contactin (CNTN) families are cell adhesion molecules (CAMs;
Table 2). In broad terms, CAMs are membrane proteins
that extend into the extracellular space and facilitate physical
interaction with other cells or with the extracellular matrix.
NRXNs are enriched in the presynaptic compartment whereas
NLGNs are enriched postsynaptically (Ichtchenko et al., 1995).
The two families of proteins interact to form a transsynaptic
bridge, linking pre to post, and are thought to be early
contributors to synapse formation (Scheiffele et al., 2000;
Levinson and El-Husseini, 2005). Within their respective
compartments, these proteins also interact with components of
the active zone and postsynaptic density, including components
linked to neurotransmitter vesicle release, and neurotransmitter
receptors and scaffolding proteins (Irie et al., 1997; Prange et al.,
2004). The NRXN family includes three genes (NRXN1-3) that
can be expressed via one of two promoters, termed α and β.
Transcription via the α promoter yields a longer protein with six
laminin/neurexin/sex hormone (LNS) binding domains, whereas
transcription via the β promoter yields a shorter protein with a
single LNS binding domain (Tabuchi and Südhof, 2002). NRXN
proteins also contain extracellular epidermal growth factor (EGF)
repeats and a PSD-95-Discs Large-zona occludens-1 (PDZ)
binding motif. The NRXN family also includes the contactin
associated protein (CNTNAP) genes that encode CASPR proteins
that are structurally similar with LNS binding domains, EGF
repeats, and a PDZ binding motif (Gennarini et al., 2017). The
NLGN family includes five genes in humans (NLGN1-3, 4X, 4Y;
Bolliger et al., 2001) and four genes in mice (Nlgn1-4; Bolliger
et al., 2008). NLGN proteins contain an intracellular PDZ binding
motif and an extracellular acetylcholinesterase domain (Levinson
and El-Husseini, 2005).
Members of the NLGN family show some synapse specificity,
with NLGN1 enriched at excitatory synaptic contacts, and
NLGN2 at inhibitory contacts (Song et al., 1999; Varoqueaux
et al., 2004; Chubykin et al., 2007). NLGN3 can be localized
at either type of contact (Budreck and Scheiffele, 2007), while
NLGN4 is enriched at central and peripheral inhibitory contacts
(Hoon et al., 2011). This preferential enrichment pattern points
to a role in synapse specificity. Indeed, Nrxn and Nlgn protein
families have been shown to influence the “balance” of excitation
and inhibition in vitro (Prange et al., 2004; Levinson and El-
Husseini, 2005), and in animal models (Hines et al., 2008;
Dahlhaus et al., 2010; Pizzarelli and Cherubini, 2011). Specific
genes within NRXN and NLGN families of CAMs have been
implicated in the etiology of ASD, including: NLGN1, NLGN2,
NLGN3, NLGN4, NRXN1, NRXN2, CNTNAP2, and CNTNAP4
(Jamain et al., 2003; Banerjee et al., 2014; Baig et al., 2017).
Alterations to NRXN and NLGN family members in ASD range
from de novo mutations to common genetic variants, and include
polymorphisms, variants, frameshift mutations, truncations,
and deletions. Although validated in multiple independent
studies these mutations are relatively rare (Jamain et al., 2003;
Hedges et al., 2012; Banerjee et al., 2014). CNTNAP2 (Arking
et al., 2008; Anney et al., 2012) and NRXN1 (Sanders et al.,
2011) in particular have been validated through genome-wide
association studies.
Several animal models have been developed to examine the
contributions of Nrxn to excitatory signaling and the symptoms
of ASD (Cattabeni et al., 1999; Kattenstroth et al., 2004; Grayton
et al., 2013; Dachtler et al., 2014) but information about inhibitory
signaling in these models is limited. Ablation of individual
Nlgn genes in mouse models have somewhat subtle effects
on development and behavior likely due to compensation,
yet combined deletion of Nlgn1-3 results brainstem inhibitory
dysfunction leading to respiratory failure (Varoqueaux et al.,
2006). Detailed examination of Nlgn1 KO mice revealed
an impairment in N-methyl-D-aspartate (NMDA) signaling
consistent with enrichment at excitatory synapses, along with
repetitive behavior and impaired spatial memory (Blundell et al.,
2010). Nlgn3 KO mice show a lack of social novelty preference
and reduced vocalization, accompanied by an olfactory deficit
(Radyushkin et al., 2009).
Expression of one of the Nlgn3 mutations identified in autism
(R451C substitution) was shown to result in impaired social
interactions paralleled by an increase in inhibitory synaptic
transmission, leaving excitatory synapses unaffected (Tabuchi
et al., 2007). However, a follow up study was not able to reproduce
the deficits in social interaction in Nlgn3R451C mice (Chadman
et al., 2008). In these studies Nlgn3R451C mice were shown to
have impairments in ultrasonic vocalizations, and other subtle
indications of impaired development (Chadman et al., 2008).
In another follow up study the Nlgn3R451C mutation was
backcrossed onto a different background strain (129S2/SvPasCrl),
which reproduced deficits in social interaction (Jaramillo et al.,
2014). The discrepancies among these studies may be attributed
to subtle differences in methodology, particularly given that the
social interaction tasks in mice are very sensitive to variations
in protocol. Nlgn4 loss of function mutation results in deficits
in reciprocal social interaction and vocalizations (Jamain et al.,
2008).
Increased expression of NLGNs has also been shown to result
in several abnormalities relevant to ASD, including behavioral
deficits. Increased expression of Nlgns1-4 was shown to result
from KO of the eukaryotic translation initiation factor 4E-
binding protein 2 (4E-BP2; Gkogkas et al., 2013). 4E-BP2 is a
repressor of eukaryotic translation initiation factor 4E (eIF4E),
which is downstream in the signaling cascade of mammalian
target of rapamycin (mTOR). 4E-BP2 KO mice exhibit an
altered ratio of excitatory to inhibitory synapses, along with
deficits in social interaction, ultrasonic vocalizations, and the
occurrence of repetitive behaviors (Gkogkas et al., 2013). In
other studies, transgenic mice with an overexpression of Nlgn1
and Nlgn2 were generated to determine the effect of specific
single Nlgns on the excitatory to inhibitory ratio (Hines et al.,
2008; Dahlhaus et al., 2010). Mice with enhanced expression
of Nlgn1 show deficits in memory acquisition, along with
enlarged excitatory synapse morphology and enhanced excitatory
signaling (Dahlhaus et al., 2010). Mice with the enhanced
expression of Nlgn2 were found to have behavioral symptoms of
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neurological disorders similar to those seen in RS (limb clasping),
decreased social interaction, repetitive behaviors, as well as
decreased viability. Immunohistochemical, electron microscopic
and electrophysiological analysis of the Nlgn2 overexpressing
mice revealed a shift in the excitatory to inhibitory ratio toward
inhibition, with an increase in inhibitory synaptic contacts and
overall enhancement of inhibitory responses (Hines et al., 2008).
Nlgn2 has been shown to directly interact with gephyrin, which
is known to aid in localizing and stabilizing GABAARs (Pizzarelli
and Cherubini, 2011). Of particular interest, a recent study has
shown that the NLGN2 R705C mutation identified in autism
disrupts the interaction with gephyrin and thus has consequences
for GABAAR function (Nguyen et al., 2016).
Although associated with contactins (discussed below),
CNTNAP proteins are members of the NRXN family based on
structural similarity, and are also associated with ASD (Katidou
et al., 2008; Burbach and van der Zwaag, 2009). CNTNAP genes
code for CASPR proteins which act as CAMs. Similar to NRXNs,
CASPR proteins contain LNS domains, and EGF-like repeats, but
also contain discoidin homology domains, and an extracellular
fibrinogen-like domain (Katidou et al., 2008; Burbach and van der
Zwaag, 2009). Within the CASPR cytoplasmic tail is a protein 4.1
biding site and class II PDZ binding motif (Katidou et al., 2008;
Burbach and van der Zwaag, 2009).
Genetic analysis of CNTNAP2 in ASD has revealed deletions
producing a frameshift mutations leading to early introduction
of a stop codon (Strauss et al., 2006; Watson et al., 2014).
This causes a complete loss of function in the CASPR2
protein in homozygous individuals. Following this implication
of CNTNAP2, several studies have shown a link between
CNTNAP2 and ASD risk (Alarcón et al., 2008; Arking et al.,
2008; Bakkaloglu et al., 2008; Vernes et al., 2008). In human
populations, CNTNAP2 heterozygous mutations do not always
produce symptoms of ASD, while homozygous individuals for
the mutation display ASD symptoms, along with epilepsy,
facial dysmorphisms, severe intellectual disability and impaired
language (Rodenas-Cuadrado et al., 2016). CNTNAP2 has been
shown to cluster voltage gated potassium channels at nodes of
Ranvier (Poliak et al., 1999), and influence dendritic arborization,
synapse strength, and plasticity (Anderson et al., 2012). In mice,
homozygous KO of CNTNAP2 causes increased grooming and
digging (repetitive behaviors), impaired ultrasonic vocalization,
less time interacting, and epilepsy (Peñagarikano et al., 2011).
The behavioral changes in CNTNAP2 KO mice are paralleled
by a decrease in PV-positive interneurons, suggesting that
CNTNAP2 plays role in GABAergic interneuron development
(Peñagarikano et al., 2011).
Both de novo and maternally inherited deletions have been
detected in ASD populations in a related family member,
CNTNAP4 (O’Roak et al., 2012). CASPR4 protein is enriched
in the presynaptic terminals of developing interneurons, and
CNTNAP4 KO mice show a reduction in GABAergic signaling
from PV-positive interneurons in the cortex (Karayannis et al.,
2014). CNTNAP4 KO mice were also found to have enhanced
midbrain dopamine release into the nucleus accumbens,
paralleled by increased responsiveness to startle and enhanced
sensory motor gating (linked to schizophrenia), along with
excessive grooming behavior (Karayannis et al., 2014). Treatment
of CNTNAP4 KO mice with an α1-selective positive allosteric
modulator at GABAARs, indiplon, ameliorated the sensory-
motor gating phenotype (Karayannis et al., 2014).
CASPR proteins interact with the contactin (CNTN) family of
proteins. CNTN proteins perform diverse functions in the CNS
including myelination, synapse formation, and plasticity. This
group of proteins, like the NRXNs and NLGNs, is also adhered
to the cell membrane (Zuko et al., 2013). Duplication or deletion
mutations in CNTN4 near CNTN3 have been implicated in the
development of ASD, with more rare mutations in CNTN5 and
6 also being implicated (Banerjee et al., 2014). CNTN4 plays a
role in the growth and development of axons and maintenance
of mature networks. In contrast to CNTNAP mutations, loss of a
single functional copy of CNTN4 can cause developmental delays
(Roohi et al., 2009).
Scaffolding Proteins: SHANK Family of
Proteins
Mutations in genes encoding scaffolding proteins, such as
the SHANK family of proteins have also shown connection
to the development of ASD (Table 2; Leblond et al., 2012;
Sato et al., 2012; Monteiro and Feng, 2017). Scaffolding
proteins function in clustering and anchoring synaptic proteins
including neurotransmitter receptors, and serve to link post
synaptic receptors with downstream signaling components. The
SHANK family includes three genes (SHANK1-3), that can be
alternatively spliced to generate multiple Shank protein variants
(Monteiro and Feng, 2017). Full-length Shank proteins are
composed of 5–6 N-terminal ankyrin repeat domains, a Src
Homology 3 (SH3) domain, a PDZ domain, a proline-rich
region and a C-terminal sterile alpha motif (SAM) domain
(Monteiro and Feng, 2017). Based on the interactions of these
domains, Shank can bind an estimated 30 synaptic partners,
including other scaffold molecules, glutamatergic receptors, and
cytoskeletal proteins (Ehlers, 1999; Sheng and Kim, 2000; Baron
et al., 2006; Gundelfinger et al., 2006). Shank proteins are
expressed in the postsynaptic compartment of glutamatergic
synapses. As central regulators of receptors, signaling machinery,
and the cytoskeleton at excitatory synapses, Shank proteins have
been shown to be involved in spine morphogenesis, synapse
formation, and glutamate receptor trafficking (Naisbitt et al.,
1999; Sala et al., 2001, 2005; Gerrow et al., 2006; Verpelli et al.,
2011).
Mutations in all three SHANK family members have been
connected with ASD and/or associated disorders (Ting et al.,
2012; Leblond et al., 2014). SHANK1 deletions have been
detected in ASD males (Sato et al., 2012), while multiple studies
have detected de novo mutations and deletions in SHANK2
(Berkel et al., 2010; Pinto et al., 2010; Leblond et al., 2012).
SHANK3 is even more strongly implicated in ASD and related
disorders. SHANK3 haploinsufficiency is responsible for Phelan
McDermid syndrome, which is characterized by intellectual
disability, hypotonia, epilepsy, and ASD characteristics (Phelan
and McDermid, 2012). In varied ASD populations, de novo
mutations, truncations and terminal deletions have been detected
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in SHANK3 (Durand et al., 2007; Boccuto et al., 2013; Leblond
et al., 2014). SHANK3 has also been identified in genome wide
association studies of ASD (Connolly et al., 2017).
Modeling of these mutations in mice has revealed that many
of the mutant proteins do not achieve their synaptic localization,
and are retained in the cell body or nucleus (Grabrucker et al.,
2014), and that a variety of SHANK manipulations in vivo can
produce ASD relevant phenotypes (Sala et al., 2015). SHANK2
mutations in mice result in upregulation of glutamate receptors
and a decrease in synaptic transmission (Schmeisser et al., 2012).
Behaviorally, SHANK2 mutant mice are hyperactive, exhibit
repetitive grooming, and have impairments in social interactions
and vocalizations (Schmeisser et al., 2012). SHANK3 KO leads
to reduction in spine volume, a decrease in the thickness of
the postsynaptic density, and a loss of dendritic spines (McGee
et al., 2014). SHANK3 KO mice show abnormal social behaviors,
and impairments in learning and memory (Bozdagi et al., 2010).
SHANK3 mutations identified in patients with ASD show a
modification in dendritic spine induction and morphology as well
as actin accumulation in spines affecting growth cone motility
which is nicely paralleled by the mouse model (Durand et al.,
2007). SHANK3 duplication in mice leads to hyperactivity and
spontaneous seizures much like human subjects who have small
duplications in the SHANK3 locus (Han et al., 2013). KO mice for
SHANK3 showed abnormal communication patterns, repetitive
behaviors, and impaired learning (Banerjee et al., 2014; McGee
et al., 2014). Again, these behaviors are consistent with the
phenotype of ASD in humans.
SHANK3 interacts with NLGN genes as a binding partner
to play role in synaptic plasticity (Meyer et al., 2004), and
SHANK3 is also involved in synapse formation and this results
in an increase of excitatory signals (Arons et al., 2012). Although
the link of Shank proteins to excitatory synapse function is
clear, studies have not thoroughly investigated the impact that
SHANK mutations may have on interneuron or inhibitory
synapse function, downstream of excitation. Further studies
on the existing SHANK mouse models generated may be
helpful in examining the relationship between excitatory synapse
dysfunction and downstream impacts on inhibitory signaling.
15q11-q13 Locus Genes: GABAA
Receptor Subunits
A known unstable genetic locus, termed 15q11-q13, is located on
chromosome 15 and contains UBE3A (Ubiquitin-protein ligase
E3A), and three GABAAR subunit genes (GABRB3, GABRA5,
and GABRG3; Table 2). The 15q11-q13 region is subject to
imprinting and recombination, and is regarded as one of the most
complex regions in the genome (Martin et al., 2000). The partial
trisomy of chromosome 15 was first reported as a syndrome in
1975 (Hecht, 1975). The syndrome produced by duplication of
15q11-q13, termed Dup15q, includes global developmental delay,
social communication deficits, intellectual disability, with a high
incidence of epilepsy and/or infantile spasms (Urraca et al., 2013).
Children with Dup15q generally meet the diagnostic criteria for
ASD diagnosis (Urraca et al., 2013), and several studies have
now shown that duplications in 15q11-q13 are one of the most
common copy number variants linked with ASD, which have
been replicated in genome wide association studies (Cook et al.,
1997; Park and Bolton, 2001; Kwasnicka-Crawford et al., 2007;
Depienne et al., 2009; Sanders et al., 2011). Duplications in
this region can take one of two forms, two extra copies of the
15q11.2-q13.1 region of maternal origin on a supernumerary
chromosome (isodicentric), or one or more extra copies on the
q arm of chromosome 15 (DiStefano et al., 2016). 15q11-q13
loss of activity is discussed specifically below in the “Angelman
Syndrome” section.
Duplication specifically of the region containing GABAARs
leads to a prediction of excessive inhibitory neurotransmission
due to gene dosage; however, an in vitro model of 15q duplication
displayed reduced transcripts for GABRB3 (and other nearby
genes) due to impaired homologous pairing (Meguro-Horike
et al., 2011). The symptoms of individuals with Dup15q also are
suggestive of altered GABAergic control of oscillatory activity.
Multiple reports have demonstrated enhanced activity in β
frequency bands (12–30 Hz) of the EEG, with spontaneous β
oscillations visually evident (Urraca et al., 2013). A further study
demonstrated that enhanced power in the upper β frequencies
(20–30 Hz) was significantly related to epilepsy diagnosis in
Dup15q (Frohlich et al., 2016). The enhanced power and
spontaneous oscillations noted in Dup15q are similar to the
effects seen following treatment with benzodiazepines and other
allosteric modulators of GABAARs, although none of the patients
were on such medication (Urraca et al., 2013; Al Ageeli et al.,
2014; Frohlich et al., 2016). Further, since the EEG β phenotype is
observed with both maternal and paternal duplication cases, it is
likely that this phenotype results from altered GABAAR function
and not the maternally expressed (non-imprinted) Ube3a gene
(Frohlich et al., 2016).
Examination of the seizure phenotype in patients with Dup15q
have indicated about 63% of those with isodicentric mutations
have seizures, with the majority of these cases having multiple
seizure types (81%), and with a relatively high rate of infantile
spasms (42%; Conant et al., 2014). In contrast, only about
25% of interstitial mutation type Dup15q patients had seizures
(Conant et al., 2014). This study also revealed that broad
spectrum anti-epileptic drugs, and those that block voltage
gated sodium channels (carbamazepine and oxcarbazepine)
were typically effective, whereas typical benzodiazepines were
relatively ineffective (Conant et al., 2014). Also indicative of
abnormal GABAergic signaling, paradoxical increases in seizure
severity have been reported in isodicentric Dup15q following
treatment with pregabalin (Di Rocco et al., 2013), a drug that
acts to increase extracellular GABA by increasing the density
of GABA transporter proteins, increasing the rate of functional
GABA transport, and increasing the enzyme responsible for
making GABA (L-glutamic acid decarboxylase) as a result
of high-affinity binding to the α2-δ subunit of voltage-gated
calcium channels (Sze, 1979; Marks et al., 2009). Mouse models
mimicking human 15q11-q13 duplication exhibit features of
autism, such as poor social interaction, behavioral inflexibility,
and abnormal ultrasonic vocalizations (Nakatani et al., 2009).
Further, a mouse model with a point mutation altering the surface
stability of the GABAAR β3 subunit (GABRB3 gene product)
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displays ASD-like features and enhanced susceptibility to seizure
(Vien et al., 2015).
Indirectly reacted to the findings of loss of function of
GABAAR in Dup15q, postmortem studies from subjects with
ASD with non-specified genetic background have shown reduced
levels of [3H]-muscimol binding compared to control (Blatt
et al., 2001). Muscimol has a higher affinity for α4/δ-containing
receptors than other GABAAR (Huh et al., 1996). Recently,
expression and protein levels of subunits where found to be
significantly reduced in different regions of brains from autistic
subjects compared to age-matched controls. Protein expression
of α1, α2, α3, α5, and β3 subunits were reduced in the parietal
cortex whereas in the frontal cortex α1, α4, α5, and β1 subunits
were reduced (Fatemi et al., 2009, 2010, 2013). These data would
suggest a GABAergic hypofunction and in particular, a reduced
tonic inhibition of patients with autism.
Other rare mutations implicated in ASD are directly or
indirectly linked to GABAergic signaling, including, mutations in
SLC12A5 impacting the C-terminal regulatory domain of KCC2
(Merner et al., 2015), RIM1A (Iossifov et al., 2014) which has been
shown to modulate GABA release from interneurons (Lachamp
et al., 2009), DLX homeobox transcription factors (International
Molecular Genetic Study of Autism Consortium [IMGSAC],
2001; Liu et al., 2009) which play a role in interneuron
differentiation and induction of GABA synthesis (Pleasure et al.,
2000; Cobos et al., 2005; Paina et al., 2011), and ANK2 (Ankyrin
B; De Rubeis et al., 2014; Iossifov et al., 2014) which creates
the AIS boundary, and is involved in modifying AIS length
(Galiano et al., 2012). Collectively, these genetic and animal
model studies suggest that dysfunction in the structure and or
function of transmembrane adhesion, scaffolding, and receptor
proteins critical for creating and stabilizing synapses are major
contributors to ASD. In particular, evidence of altered inhibitory
synapse adhesion molecules, scaffolding proteins, and GABAAR
signaling is clearly implicated in ASD. Alterations in PV-
positive neuron number and/or function, and alterations in tonic
inhibition are common among multiple genetic causes of ASD,
warranting further study. Below we will explore monogenetic
NDDs with symptoms related to ASD, to examine the indications
of inhibitory synapse dysfunction more broadly.
ANGELMAN SYNDROME
Angelman syndrome (AS) is a NDD characterized by severe
mental retardation, ataxic movements, speech impairment, and
high incidence of seizures (Buiting et al., 2016). In contrast
to other NDDs, people with AS display a sociable disposition
and are prone to unprovoked bouts of laughter. AS is relatively
rare, with an incidence of somewhere between 1:12,000 and
1:20,000, accounting for about 6% of all children with mental
retardation and epilepsy (Pelc et al., 2008; Buiting et al., 2016).
AS is caused by a loss of activity within the 15q11-13 locus, and
about 70% of cases are due to a “de novo” interstitial deletion
in the long arm region, arising on the maternally inherited
chromosome (Buiting et al., 2016). The candidate gene in this
region thought to be responsible for AS is UBE3A (Table 2;
Kishino et al., 1997; Matsuura et al., 1997; Sutcliffe et al., 1997),
although three GABAAR subunit genes are also located in this
region as mentioned above. AS is a classic example of imprinting
and is most commonly caused by deletion or inactivation of
genes on the maternally inherited chromosome 15 while the
paternal copy is imprinted or silenced in the brain producing the
most severe cases, with seizures, mental and motor retardation,
dysmorphic features and microcephaly phenotype (65–70% of
probands; Kyllerman, 2013). The other two possible causes,
uniparental disomy and imprinting center mutations (10%), and
UBE3A point mutations (11%) result in more mild phenotypes
(Kyllerman, 2013). The AS diagnosis is confirmed by methylation
test or by mutation analysis of the UBE3A gene. Regardless
of mutation type, seizures occur between ages 1 and 3 years
in approximately 85% of patients and are most commonly
characterized by atypical absence, erratic myoclonic, and rare
tonic–clonic seizure types (Fiumara et al., 2010). Detailed EEG
studies of AS patients have revealed high-amplitude δ frequency
(2–3 Hz) activity, with spike and slow-wave discharges, and
a circadian pattern to epileptiform discharges, showing sleep-
activation (Kyllerman, 2013).
As discussed above, the GABAAR genes, GABRB3, GABRA5,
and GABRG3 genes (Table 2), encoding β3, α5, and γ3 subunits,
respectively, are also within the 15q11-13 locus. The presence of
this GABAAR subunit gene cluster in 15q11-13 has led to the
hypothesis that GABA neurotransmission may also be involved
in AS (Pelc et al., 2008), as well as ASD. In particular, the
GABRB3 gene is known to be associated with epilepsy in humans,
and when a deficiency of UBE3A is also present, more severe
symptoms result (Pelc et al., 2008).
The phenotype of maternal Ube3a-deficient mice resembles
human AS with motor dysfunction, inducible seizures and a
context-dependent learning deficit (Jiang et al., 1998). Using
mouse models it has been demonstrated that Ube3a-deficiency
results in reduced GABA-mediated tonic inhibition in the
cerebellum, mechanistically caused by a GAT-1 dependent
decrease of GABA concentration in the extracellular space
(Egawa et al., 2012). A recent paper elegantly examined the
contributions of Ube3a loss in specific populations of cells to the
pathophysiology of AS (Judson et al., 2016). Using conditional
deletion in mouse models it was shown that loss of Ube3a
in GABAergic interneurons, but not glutamatergic principal
cells, results in EEG abnormalities of enhanced δ, and seizures,
similar to individuals with AS. Other studies have examined
the combined Ube3a and GABRB3 effects using chromosomal
deletion spanning Ube3a to GABRB3 (includes a deletion of
the Atp10a gene; Jiang et al., 2010). Maternal (Ube3am−/p++),
but not paternal (Ube3am+/p−), deletion mice had increased
spontaneous seizure activity and abnormal EEG, along with
impairments in motor function, learning and memory, ultrasonic
vocalizations, and an anxiety-like phenotype demonstrating the
impact of GABAAR function on the severity of phenotype (Jiang
et al., 2010). The Ube3am−/p+ model has also been shown to
have an inhibitory deficit resulting from impaired vesicle cycling
in interneurons (Wallace et al., 2012). In addition to Ube3a,
examination of GABAAR β3 subunit-deficient mouse models
have also revealed a strong link between GABAARs and AS, β3
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deficient mice show 90–95% neonatal mortality, with survivors
displaying a phenotype resembling severe forms of human AS
(Homanics et al., 1997; DeLorey et al., 1998).
The maternal deletion model of AS (Ube3am−/p+) has
also been shown to result in alterations to the intrinsic
properties of neurons (Kaphzan et al., 2011). In these studies
researchers demonstrated alterations in resting membrane
potential, threshold potential, and action potential amplitude of
principal cells. The changes in intrinsic properties were paralleled
by significant increases in the expression of the voltage gated
sodium channel NaV1.6, and the AIS anchoring protein ankyrin-
G, as well as an increase in length of the AIS (Kaphzan et al.,
2011). Previous studies have shown that the AIS can adapt
to the inputs that a cell is receiving, with reduced synaptic
input resulting in elongation of the AIS (Kuba et al., 2010),
and increased excitability moving the AIS away from the cell
body (Grubb and Burrone, 2010). The AIS is also of interest in
considering GABAergic signaling, as it is the postsynaptic site of
PV-positive chandelier cell contact, and changes in the properties
of the AIS also likely effect GABAergic control at this important
site.
As with ASD, AS is also clearly linked to dysfunction of
inhibitory signaling, and in particular to dysfunction of GABAAR
subunit expression and function. Again, dysfunction of PV-
positive neurons emerges as a feature of AS. It is interesting that
despite a common biological phenotype of reduced transcripts
for GABAAR subunit genes in Dup15q ASD and AS, the EEG
phenotype differs between these two syndromes, suggesting the
need for regional, and more specific analysis of GABAAR subunit
expression and function, as well as GABAergic synapse subtypes
in these disorders.
RETT SYNDROME
Rett syndrome (RS), is a genetic disorder that leads to severe
impairments, affecting nearly every aspect of a child’s life. ASD-
like features, especially stereotyped behaviors, loss of language
skills, learning and memory deficits, loss of social skills, and
seizures are common characteristics of RS (Chahrour and
Zoghbi, 2007). RS may also include apraxia, ataxia, impaired
coordination, tremor, respiratory dysrhythmias, and sometimes
premature lethality (Chahrour and Zoghbi, 2007; Chao et al.,
2007). Not all of the symptoms of RS are present during
early postnatal development, but rather appear over stages,
following a period of developmental stagnation that typically
begins between 6 and 18 months of age (Chahrour and Zoghbi,
2007). The primary cause of RS is mutation of the gene encoding
the transcriptional repressor methyl-CpG-binding protein 2
(MeCP2; Table 2; Kozinetz et al., 1993). The MECP2 gene is
located on the X-chromosome, and since males have only one
X chromosome (instead of the two in genetic females), MECP2
mutation results in more severe symptoms, with the majority
of RS males dying shortly after birth (Meloni et al., 2000). In
females, RS represents one of the leading causes for mental
retardation (Neul and Zoghbi, 2004). Within females, the severity
of RS symptoms can vary widely depending upon the pattern of
x-chromosome inactivation (Dragich et al., 2000). It is estimated
that approximately 60–80% of females with RS have epilepsy
(Vignoli et al., 2017), with severity of the syndrome positively
correlated with the prevalence of epilepsy (Tarquinio et al., 2017).
Longitudinal studies have indicated an even higher cumulative
lifetime prevalence of epilepsy in RS, with approximately 90%
incidence evaluated using a Kaplan–Meier method (Tarquinio
et al., 2017). A fascinating link between ASD, AS, and RS was
identified when researchers found that MECP2 (along with other
factors) is required for the homologous pairing of 15q11-q13
during neuronal differentiation during the maturation process
(Meguro-Horike et al., 2011).
Researchers have developed multiple animal models to study
the underlying neuropathology associated with RS. Mecp2
deficient mice, created by deleting either exon 3, or exons 3 and 4,
replicate all the features of the human disease (Chen et al., 2001).
Truncation mutations (Mecp2308) produce a more moderate
phenotype that shows the progressive pattern of symptom
development (Shahbazian et al., 2002). It is also interesting to
note that in mouse models (Collins et al., 2004), and in human
NDDs (del Gaudio et al., 2006), increased expression of Mecp2
also produces a progressive neurological phenotype, indicating
that precisely controlled levels of Mecp2 are essential for normal
nervous system function.
Conditional, neuron specific deletion of Mecp2 in mice is
sufficient to produce symptoms of RS (Guy et al., 2001), and
the neurologic abnormalities can be reversed by activating
the Mecp2 gene later in life (Amir et al., 1999; Luikenhuis
et al., 2004). Surprisingly, despite the diversity of the features
seen in RS, recent findings also indicate that deleting Mecp2
only from GABAergic inhibitory neurons in mice is sufficient
to replicate most of the phenotypes of the human disease
(Medrihan et al., 2008). In this elegantly performed study,
researchers created a Mecp2 KO model by crossing Viaat-Cre
to Mecp2flox/+ mice. The result from this study was a loss of
Mecp2 in male Viaat-Mecp2−/y mice from more than 90%
GABAergic neurons (Chao et al., 2010). Mice with Mecp2
deficiency from GABA-releasing neurons recapitulate numerous
RS and ASD features, including repetitive behaviors, ataxia,
premature death, breathing abnormalities, and seizures. These
mice initially exhibit normal behavior, then develop forepaw
stereotyped movements, compulsive grooming, increased
sociability, impaired motor coordination, learning/memory
deficits, abnormal EEG hyperexcitability, severe respiratory
dysrhythmias, and premature lethality (Chao et al., 2010).
Specific interneuron subtypes have been shown to play
distinctive roles in RS, determined by selectively deleting
Mecp2 from either PV or SOM positive interneurons (Ito-Ishida
et al., 2015). Deletion of MeCP2 in PV+ interneurons resulted in
motor, sensory, cognitive, and social interaction deficits, whereas
deletion of MeCP2 in SOM+ interneurons resulted in seizures
and stereotypies (Ito-Ishida et al., 2015). Another recent study
was able to genetically re-express Mecp2 solely in GABAergic
neurons in a Mecp2 KO mouse, restoring inhibitory function.
GABA concentrations in the striata of 8-week-old rescue mice
were restored to wildtype levels. No behavioral seizures were seen
in the rescue mice, while EEG recordings showed that five out of
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six rescue mice had normalized activity patterns (Lu et al., 2016).
Another recent study demonstrated that KCC2 is a downstream
target of Mecp2, and that human neurons derived from stem
cells of RS patients have reduced KCC2 expression and a delayed
switch in EGABA (Tang et al., 2016).
Studies examining the neuropathology of RS have identified
strong depression of GABAergic neurotransmission in the
ventrolateral medulla (Medrihan et al., 2008), and nucleus tractus
solitarius (Chen et al., 2017) of Mecp2 null mice. Studies
in the ventrolateral medulla indicated reduced GABA release
paralleled by reduced levels of the vesicular inhibitory transmitter
transporter and reduced levels of α2 (typically synaptic) and
α4 (typically extrasynaptic) subunits of GABAARs (Medrihan
et al., 2008). In the nucleus tractus solitarius, it has been shown
that GABAAR δ subunit (typically extrasynaptic) expression is
enhanced, paralleled by enhanced responsiveness to THIP, which
selectively activates extrasynaptic GABAAR subtypes (Chen
et al., 2017). Other studies have indicated reductions in the
frequency of spontaneous inhibitory postsynaptic currents in
hippocampal recordings from symptomatic Mecp2 null mice
(Zhang et al., 2008). In addition, these studies found that Mecp2
null hippocampal circuitry was prone to hyperexcitability, as
evidenced by induction of repetitive sharp wave-like discharges
following a brief train of high-frequency stimulation (Zhang et al.,
2008).
Similar to ASD and AS, several lines of evidence also link
RS to dysfunction of inhibitory signaling. In particular, support
for the role of PV-positive interneuron dysfunction in broad
NDDs is apparent. In addition, indications of KCC2 dysfunction
are present in both ASD and RS. Evidence is accumulating
for dysfunction of specific GABAAR subunit expression and
function, with regional specificity as well, this level of analysis is
currently lacking in ASD and AS models. Studies in RS models
have highlighted an interesting parameter for consideration in
other NDD models, namely the ratio of synaptic to extrasynaptic
GABAergic signaling (Medrihan et al., 2008; Chen et al., 2017).
Changes in subunit expression and mode of inhibition (phasic
versus tonic) as a direct result of mutation, or as a plastic or
homeostatic adaptation could result in alterations in network
function leading to some of the electrophysiological, EEG, and
phenotypic manifestations of NDDs.
DRAVET SYNDROME
Developmental epilepsies are also considered in the umbrella
of NDD, due to the high incidence of epilepsy in prototypical
NDD, as well as the developmental factors known to contribute
to epileptogenesis (Bozzi et al., 2012). Further, just as epilepsy
has a high occurrence in NDD populations, NDD features are
also commonly observed in epilepsy syndromes. In addition
to the prototypical NDDs, consideration of the phenotypes of
developmental epilepsy syndromes will provide insight into the
cellular and circuit dysfunction in NDD. Dravet syndrome (DS),
formerly known as Severe Myoclonic Epilepsy of Infancy (SMEI),
is a rare form of epilepsy that begins in the first year of life
with frequent and/or prolonged seizures (Han et al., 2012). At
early onset, DS is characterized by both febrile and non-febrile
seizures, and progresses to myoclonic and/or partial seizures,
psychomotor delay, and ataxia (Selmer et al., 2009). Patients
with DS also have a high risk of sudden unexpected death in
epilepsy (SUDEP; Shmuely et al., 2016). DS is also characterized
by cognitive impairment, motor deficits, hyperactivity and/or
impulsiveness, and in rare cases can include autistic-like
behaviors (Han et al., 2012). The prevalence of DS is 1:15,700
individuals, with around 75% of patients bearing a mutation in
their SCN1A gene, which encodes the α1 subunit of the voltage
gated sodium channel (NaV1.1; Wu et al., 2015). The remaining
25% of DS cases have been linked to mutations in GABRG2,
GABRA1 (Table 2), protocadherin 19 (PCDH 19), and Syntaxin
Binding Protein-1 (STXBP1; Carvill et al., 2014). Mutations in
SCN1A are also responsible for Genetic Epilepsy with Febrile
Seizures Plus (GEFS+), which is an autosomal dominant form of
epilepsy, typically less severe than DS (Hawkins et al., 2016; Kang
and Macdonald, 2016). These findings indicate additional factors
beyond SCN1A mutation that contribute to the occurrence and
severity of the phenotype (Hawkins et al., 2016; Kang and
Macdonald, 2016). A recent human study using single and paired
pulse transcranial magnetic stimulation has found an absence of
short interval intracortical inhibition in DS patients, suggestive
of reduced cortical GABAergic neurotransmission (Stern et al.,
2017).
Mouse models of DS (Scn1a+/−) are characterized to
have spontaneous seizures, including thermally evoked seizures
(Yu et al., 2006; Oakley et al., 2009), and as well as
behavioral phenotypes relevant to ASD (Han et al., 2012).
Electrophysiological assessment of DS models has revealed
a selective loss of sodium currents in GABAergic inhibitory
neurons, resulting in reduced excitability of interneurons
and thus reduced GABAergic neurotransmission (Yu et al.,
2006; Kalume et al., 2007; Cheah et al., 2012; Han et al.,
2012). Field recordings in Scn1A+/− mice have demonstrated
hyperexcitability of hippocampal circuits in both the pre-epileptic
and epileptic periods (Liautard et al., 2013). Similar to the
human variation in epilepsy severity, mouse models of SCN1A
dysfunction, have been shown to have a strain dependent
epilepsy phenotype, raising the possibility of additional factors
contributing to pathogenesis (Hawkins et al., 2016). Scn1a+/−
mice on 129 background have no readily detectable phenotype
and a normal lifespan, while Scn1a+/− F1 129/C57Bl6 hybrid
mice experience spontaneous and hyperthermia-induced seizures
and high rates of premature death. Genetic mapping comparing
Scn1A+/− mutations on 129 versus F1 hybrid backgrounds
identified multiple modifier loci, followed by RNA-Seq of a loci
of interest on chromosome 5 (Hawkins et al., 2016). RNA-Seq
revealed three genes with significant differences in total gene
expression between Scn1A deletion on the two backgrounds,
including the α2 subunit of GABAARs, associating low Gabra2
expression with the B6 allele and reduced survival of Scn1A
mutants on this background (Hawkins et al., 2016). These studies
also showed that clobazam, which has preferential affinity for
the GABAAR α2 subunit, normalized the temperature threshold
for hyperthermia-induced seizures in Scn1a+/− mice (Hawkins
et al., 2016). Compared to wildtype mice, Scn1a+/− mice
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displayed behavioral/social deficits as shown by circling behavior
and less time spent in open arms in an elevated plus maze. These
stereotypical behaviors are marked as autistic traits, indicating
that DS does have shared symptomatology (Han et al., 2012).
PV-positive and SOM-positive fast-spiking interneurons have
also been found to have reduced excitability in Scn1a+/− mice,
leading to reduced GABAergic inhibition (Tai et al., 2014).
Greater understanding of Scn1a localization and function may
also reveal insights about pathogenesis in DS. The protein
encoded by Scn1a, the α1 subunit of NaV1.1, has been localized to
the AIS, particularly in GABAergic interneurons (Duflocq et al.,
2008; Lorincz and Nusser, 2008). AIS dysfunction is a proposed
mechanism of neuropathology in epilepsy (Wimmer et al., 2010;
Kole and Stuart, 2012), and chandelier cell cartridges opposed to
α2 containing GABAARs are known to mediate inhibitory control
at this site (Nusser et al., 1996; Freund and Katona, 2007; Gao
and Heldt, 2016), suggesting that GABAergic dysfunction at the
AIS may be a key factor in epilepsy. Of particular interest, studies
have also shown that the benzodiazepine clonazepam is effective
at reducing the ASD-like features of the Scn1a+/− mice (Han
et al., 2012).
Examination of developmental epilepsies, alongside NDDs
with epilepsy as an associated symptom is useful in elucidating
common mechanisms. De novo mutation of SCN2A was
also recently identified using exome sequencing of ASD
samples (De Rubeis et al., 2014; Iossifov et al., 2014), further
suggesting that the AIS may be a key site to evaluate in
NDDs. As we have seen with NDD, developmental epilepsy
syndromes such as DS also highlight GABAergic dysfunction
as a key pathogenic mechanism. Again a common indication
of PV-positive interneuron dysfunction is revealed, drawing
commonality with ASD, AS, and RS. Greater understanding of
the specific roles of interneuron subtypes, subcellular domains of
inhibition, and GABAAR subunits in these disorders may help
to further advance our understanding, and improve therapeutic
strategies in NDDs.
VERY RARE MUTATIONS AND
ASSOCIATED DISORDERS
Insight into NDDs may also be gleaned by examining rare
genetic causes and disorders. Of particular interest, mutations
in the ARHGEF9 gene (Table 2) have been reported to result
in NDDs with varied behavioral symptoms (Alber et al.,
2017).The ARHGEF9 gene codes for the GDP/GTP exchange
factor collybistin (also known as HPEM2 in humans), which
is a neuron specific RhoGEF. All collybistin isoforms possess
three major functional domains: an N-terminal SH3 domain,
a GEF domain, and a PH domain. Through these domains,
collybistin has been shown to interact with gephyrin, neuroligin-
2, and the GABAAR α2 subunit, playing an important role
in clustering of GABAARs at inhibitory synapses (Saiepour
et al., 2010). To this point, 18 patients have been described to
have either point mutations, chromosomal rearrangements and
deletions involving ARHGEF9, with a range of manifestations
including ASD (Bhat et al., 2016; Machado et al., 2016), behavior
disorders (ADHD, anxiety, aggression; Kalscheuer et al., 2009;
Lesca et al., 2011), intellectual disability (Kalscheuer et al., 2009;
Lesca et al., 2011; Marco et al., 2011; Shimojima et al.,
2011; de Ligt et al., 2012; Lemke et al., 2012), hyperekplexia
(Harvey et al., 2004; Marco et al., 2008), and infantile epilepsy
(Harvey et al., 2004; Kalscheuer et al., 2009; Lesca et al., 2011;
Shimojima et al., 2011). The majority of patients identified are
male, and those that are female have been shown to have a near
complete X-inactivation in favor of the affected gene (Marco et al.,
2008; Kalscheuer et al., 2009). Collybistin KO mice recapitulate
some aspects of the behavioral syndrome including anxiety-like
behavior, learning deficits, and seizures (Papadopoulos et al.,
2007; Papadopoulos and Soykan, 2011). Related to the collybistin
mutations, rare mutations have also been identified in gephyrin
associated with diverse NDD diagnoses (Table 2), including
ASD, seizures, and schizophrenia (Lionel et al., 2013). Gephyrin
KO mice die shortly after birth, and exhibit a phenotype of
tactile-hyperresponsivity and difficulty breathing consistent with
glycinergic signaling deficits (Feng et al., 1998). In general, further
information is required to understand the detailed contribution
of collybistin, gephyrin and other inhibitory synapse organizers
in specialized subtypes of GABAergic synapses, and NDD. For
both collybistin and gephyrin, studying the effects of the human
mutations in mouse models may yield more clarity into the
role of these proteins in NDD. Other rare mutations implicated
in NDDs are indirectly linked to GABAergic scaffolding and
signaling, including NONO (Mircsof et al., 2015; Reinstein et al.,
2016) which impacts the expression of both gephyrin and the
GABAAR α2 subunit (Mircsof et al., 2015). The data from rare
NDD syndromes solidify direct and indirect links between NDDs
and the proteins responsible for inhibitory GABAAR signaling.
DISCUSSION
Throughout this review we have identified commonalities in
GABAergic signaling dysfunction in diverse NDDs. Specific
perturbation in GABAergic signaling are emerging as ribs of
commonality in these diverse disorders. One emerging rib centers
on perturbations in the developmental excitatory to inhibitory
shift in EGABA, caused by the onset of KCC2 expression. Studies
have now directly indicated SLC12A5 gene (KCC2) mutation in
ASD, with the C-terminus being impacted (Merner et al., 2015).
Recent examination of the molecular structure of KCC2 reveals
the C-terminus to be important for dimerization and function
(Agez et al., 2017). Modeling of ASD and RS associated mutations
has also revealed a delay in the chloride reversal associated
with alterations in KCC2 expression and function, producing
corresponding alterations in neuronal signaling (Tang et al., 2016;
Amin et al., 2017). Environmental models of ASD, including
maternal immune activation and valproic acid exposure have
also indicated reductions in KCC2 expression and delays in
the shift to inhibitory GABA (Corradini et al., 2017; Li et al.,
2017). Clinical Trials of bumetanide, a high affinity inhibitor of
NKCC1, have been successful in reducing the core symptoms
of ASD (Lemonnier et al., 2012, 2017). A second emerging rib
is the control of excitation by PV-positive cells. PV positive
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cells contact sites at or near action potential generation in
neurons, exerting powerful control over excitatory firing patterns
(Figure 1). A number of studies have indicated perturbations
in PV-positive cells in NDD populations and mouse models
(Peñagarikano et al., 2011; Karayannis et al., 2014; Hashemi et al.,
2017; Soghomonian et al., 2017; Vogt et al., 2017; Ariza et al.,
2018). While several studies have indicated a loss of PV-positive
cells, some evidence suggests that it may be a reduction in PV
expression, bringing cells below the detection threshold (Filice
et al., 2016). These studies are supported by the demonstration
that knockout of PV in the mouse leads to behavioral phenotypes
relevant to human ASD (Wöhr et al., 2015). A third emerging
rib is the role of tonic inhibition (Figure 2, left), early in
development and in NDDs. Studies have identified alterations in
the expression of tonic GABAAR subunits in human populations
(Fatemi et al., 2014), as well as deficits in tonic inhibition in
mouse models of NDD (Olmos-Serrano et al., 2011; Egawa
et al., 2012; Martin et al., 2014; Vien et al., 2015; Zhong et al.,
2015; Bridi et al., 2017). Gaboxadol, a GABAAR agonist with
preferential activity at δ-containing receptors, is being examined
in clinical trials for patients with Fragile-x and AS (Ligsay et al.,
2017).
Despite these emerging ribs, our understanding of the
details of inhibitory signaling lags behind that which is
known about excitatory signaling. In particular, further
investigation of regional or subtype specific deficits in GABAergic
signaling is warranted in in NDD populations and animal
models. More specific information about GABAAR subunit
alterations would provide insights about which modes of
inhibition, and which subtypes of inhibitory synapses may
be contributing to NDDs. Investigations comparing both
phasic and tonic forms of inhibition across animal models
of NDD would be illuminating, as tonic inhibition plays an
important and powerful role in controlling brain activity but
is understudied. In addition, subtypes of synaptic GABAARs,
including somatic and AIS synapses, are known to have
a powerful role in coordinating neuronal activity patterns,
but we are just beginning to understand the roles of these
synapses, how they are specified, how they develop, and
their possible contributions to NDDs. In addition, there are
many key adhesion, and scaffolding proteins required for the
aforementioned processes at specific inhibitory synapse subtypes,
including neuroligins, dystroglycan, dystrophin, gephyrin, and
collybistin, among others. Increasing our understanding of
these key proteins involved in the formation, maintenance, and
function of specific inhibitory synapses will also advance our
understanding of how subtypes impact neurodevelopment more
globally.
Further, assessments of specific interneuron function also
seem promising, with evidence pointing toward PV-positive
interneuron dysfunction as a key factor mentioned above. In
particular, it may be important to examine the mechanisms
causing changes in PV expression, as well as understand
the functional implications of such changes to neuronal
circuit activity. In addition, analysis of markers for other
subtypes of interneurons in NDD and mouse models have
not been described. In particular, analysis of interneuron
targeting interneurons that have disinhibiting effects on network
signaling is lacking in NDD populations and models. This
is of particular relevance as a recent study has shown that
Nav1.2 (SCN2A), which bears an ASD related mutation (De
Rubeis et al., 2014), is enriched in inhibitory cells that
innervate other interneurons (Yamagata et al., 2017). Analysis
of circuit level dysfunction in NDD populations and models
is also currently focused on seizures and epilepsy, and more
global assessment of patterned oscillatory activity may provide
the next needed advance following specific inhibitory mode,
interneuron, and synapse subtype assessments. In particular,
systematic assessment of oscillatory activity across multiple
mouse models of NDDs may provide illuminating insights
into commonalities and distinctions. Also of importance is to
evaluate and/or manipulate circuit activity during execution of
specific behaviors relevant to NDD, allowing for further insight
into the mechanisms producing symptoms, and promoting
novel therapeutic approaches by modulating specific circuits to
correct perturbations in oscillatory activity. Advances in our
understanding of GABAergic signaling in normal development
and in NDD models and populations will ultimately advance our
therapeutic strategies, improving patient outcomes.
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